- Home
- RARE vs NNI Comparison
RARE vs NNI Comparison
Compare RARE & NNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- NNI
- Stock Information
- Founded
- RARE 2010
- NNI 1978
- Country
- RARE United States
- NNI United States
- Employees
- RARE N/A
- NNI N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- NNI Finance: Consumer Services
- Sector
- RARE Health Care
- NNI Finance
- Exchange
- RARE Nasdaq
- NNI Nasdaq
- Market Cap
- RARE 3.6B
- NNI 4.1B
- IPO Year
- RARE 2014
- NNI 2003
- Fundamental
- Price
- RARE $33.84
- NNI $110.89
- Analyst Decision
- RARE Strong Buy
- NNI Hold
- Analyst Count
- RARE 15
- NNI 1
- Target Price
- RARE $95.93
- NNI $98.00
- AVG Volume (30 Days)
- RARE 748.6K
- NNI 63.2K
- Earning Date
- RARE 05-01-2025
- NNI 05-08-2025
- Dividend Yield
- RARE N/A
- NNI 1.01%
- EPS Growth
- RARE N/A
- NNI 109.22
- EPS
- RARE N/A
- NNI 5.02
- Revenue
- RARE $560,230,000.00
- NNI $1,354,961,000.00
- Revenue This Year
- RARE $19.15
- NNI $11.66
- Revenue Next Year
- RARE $32.11
- NNI $4.49
- P/E Ratio
- RARE N/A
- NNI $22.09
- Revenue Growth
- RARE 29.01
- NNI 15.70
- 52 Week Low
- RARE $33.69
- NNI $92.24
- 52 Week High
- RARE $60.37
- NNI $127.32
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- NNI 42.52
- Support Level
- RARE $36.71
- NNI $109.97
- Resistance Level
- RARE $39.21
- NNI $114.42
- Average True Range (ATR)
- RARE 1.34
- NNI 2.15
- MACD
- RARE -0.32
- NNI -0.56
- Stochastic Oscillator
- RARE 2.19
- NNI 12.22
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About NNI Nelnet Inc.
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.